Preclinical investigation reveals that alpha-enolase drives proliferation and metastasis in non-small cell lung cancer, highlighting its potential as a targeted therapeutic candidate.
This study showed that ENO1 is responsible for NSCLC proliferation and metastasis; thus, ENO1 might serve as a potential molecular therapeutic target for NSCLC treatment.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: